HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Human Cytomegalovirus Tegument Protein pp65 (pUL83) Dampens Type I Interferon Production by Inactivating the DNA Sensor cGAS without Affecting STING.

Abstract
The innate immune response plays a pivotal role during human cytomegalovirus (HCMV) primary infection. Indeed, HCMV infection of primary fibroblasts rapidly triggers strong induction of type I interferons (IFN-I), accompanied by proinflammatory cytokine release. Here, we show that primary human foreskin fibroblasts (HFFs) infected with a mutant HCMV TB40/E strain unable to express UL83-encoded pp65 (v65Stop) produce significantly higher IFN-β levels than HFFs infected with the wild-type TB40/E strain or the pp65 revertant (v65Rev), suggesting that the tegument protein pp65 may dampen IFN-β production. To clarify the mechanisms through which pp65 inhibits IFN-β production, we analyzed the activation of the cGAS/STING/IRF3 axis in HFFs infected with either the wild type, the revertant v65Rev, or the pp65-deficient mutant v65Stop. We found that pp65 selectively binds to cGAS and prevents its interaction with STING, thus inactivating the signaling pathway through the cGAS/STING/IRF3 axis. Consistently, addition of exogenous cGAMP to v65Rev-infected cells triggered the production of IFN-β levels similar to those observed with v65Stop-infected cells, confirming that pp65 inactivation of IFN-β production occurs at the cGAS level. Notably, within the first 24 h of HCMV infection, STING undergoes proteasome degradation independently of the presence or absence of pp65. Collectively, our data provide mechanistic insights into the interplay between HCMV pp65 and cGAS, leading to subsequent immune evasion by this prominent DNA virus.IMPORTANCE Primary human foreskin fibroblasts (HFFs) produce type I IFN (IFN-I) when infected with HCMV. However, we observed significantly higher IFN-β levels when HFFs were infected with HCMV that was unable to express UL83-encoded pp65 (v65Stop), suggesting that pp65 (pUL83) may constitute a viral evasion factor. This study demonstrates that the HCMV tegument protein pp65 inhibits IFN-β production by binding and inactivating cGAS early during infection. In addition, this inhibitory activity specifically targets cGAS, since it can be bypassed via the addition of exogenous cGAMP, even in the presence of pp65. Notably, STING proteasome-mediated degradation was observed in both the presence and absence of pp65. Collectively, our data underscore the important role of the tegument protein pp65 as a critical molecular hub in HCMV's evasion strategy against the innate immune response.
AuthorsMatteo Biolatti, Valentina Dell'Oste, Sara Pautasso, Francesca Gugliesi, Jens von Einem, Christian Krapp, Martin Roelsgaard Jakobsen, Cinzia Borgogna, Marisa Gariglio, Marco De Andrea, Santo Landolfo
JournalJournal of virology (J Virol) Vol. 92 Issue 6 (03 15 2018) ISSN: 1098-5514 [Electronic] United States
PMID29263269 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2018 American Society for Microbiology.
Chemical References
  • Interferon Type I
  • Membrane Proteins
  • Phosphoproteins
  • STING1 protein, human
  • Viral Matrix Proteins
  • cytomegalovirus matrix protein 65kDa
  • Nucleotidyltransferases
  • cGAS protein, human
Topics
  • Cytomegalovirus (genetics, immunology)
  • Cytomegalovirus Infections (genetics, immunology, pathology)
  • HEK293 Cells
  • Humans
  • Immune Evasion (genetics, immunology)
  • Immunity, Innate (genetics)
  • Interferon Type I (genetics, immunology)
  • Membrane Proteins (genetics, immunology)
  • Nucleotidyltransferases (genetics, immunology)
  • Phosphoproteins (genetics, immunology)
  • Protein Binding
  • Signal Transduction (genetics, immunology)
  • Viral Matrix Proteins (genetics, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: